Literature DB >> 24900169

Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.

Huiqiang Zhou1, Dana P Danger1, Steven T Dock1, Lora Hawley1, Shane G Roller1, Chari D Smith1, Anthony L Handlon1.   

Abstract

A series of benzisothiazole- and indolizine-β-d-glucopyranoside inhibitors of human SGLT2 are described. The synthesis of the C-linked heterocyclic glucosides took advantage of a palladium-catalyzed cross-coupling reaction between a glucal boronate and the corresponding bromo heterocycle. The compounds have been evaluated for their human SGLT2 inhibition potential using cell-based functional transporter assays, and their structure-activity relationships have been described. Benzisothiazole-C-glucoside 16d was found to be an inhibitor of SGLT2 with an IC50 of 10 nM.

Entities:  

Keywords:  Benzisothiazole- and indolizine-β-d-glucopyranoside inhibitors; SAR; SGLT2; benzisothiazole-C-glucoside

Year:  2010        PMID: 24900169      PMCID: PMC4007969          DOI: 10.1021/ml900010b

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport.

Authors:  Adam T Stearns; Anita Balakrishnan; Ali Tavakkolizadeh
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11       Impact factor: 4.052

2.  Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.

Authors:  Xiaoyan Zhang; Maud Urbanski; Mona Patel; Geoffrey G Cox; Roxanne E Zeck; Haiyan Bian; Bruce R Conway; Mary Pat Beavers; Philip J Rybczynski; Keith T Demarest
Journal:  Bioorg Med Chem Lett       Date:  2005-12-27       Impact factor: 2.823

Review 3.  Phlorizin: a review.

Authors:  Joel R L Ehrenkranz; Norman G Lewis; C Ronald Kahn; Jesse Roth
Journal:  Diabetes Metab Res Rev       Date:  2005 Jan-Feb       Impact factor: 4.876

Review 4.  From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

Authors:  Harold Bays
Journal:  Curr Med Res Opin       Date:  2009-03       Impact factor: 2.580

5.  Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.

Authors:  Yoshikazu Fujimori; Kenji Katsuno; Kazuma Ojima; Ikumi Nakashima; Shigeru Nakano; Yukiko Ishikawa-Takemura; Hiroshi Kusama; Masayuki Isaji
Journal:  Eur J Pharmacol       Date:  2009-03-10       Impact factor: 4.432

6.  Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

Authors:  Yoshikazu Fujimori; Kenji Katsuno; Ikumi Nakashima; Yukiko Ishikawa-Takemura; Hideki Fujikura; Masayuki Isaji
Journal:  J Pharmacol Exp Ther       Date:  2008-06-26       Impact factor: 4.030

7.  Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector.

Authors:  J P Condreay; S M Witherspoon; W C Clay; T A Kost
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

8.  SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states.

Authors:  Sanjay K Banerjee; Kenneth R McGaffin; Núria M Pastor-Soler; Ferhaan Ahmad
Journal:  Cardiovasc Res       Date:  2009-06-09       Impact factor: 10.787

9.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Authors:  Wei Meng; Bruce A Ellsworth; Alexandra A Nirschl; Peggy J McCann; Manorama Patel; Ravindar N Girotra; Gang Wu; Philip M Sher; Eamonn P Morrison; Scott A Biller; Robert Zahler; Prashant P Deshpande; Annie Pullockaran; Deborah L Hagan; Nathan Morgan; Joseph R Taylor; Mary T Obermeier; William G Humphreys; Ashish Khanna; Lorell Discenza; James G Robertson; Aiying Wang; Songping Han; John R Wetterau; Evan B Janovitz; Oliver P Flint; Jean M Whaley; William N Washburn
Journal:  J Med Chem       Date:  2008-02-09       Impact factor: 7.446

10.  A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

Authors:  John P H Wilding; Paul Norwood; Caroline T'joen; Arnaud Bastien; James F List; Fred T Fiedorek
Journal:  Diabetes Care       Date:  2009-06-15       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.